Samyang Biopharmaceuticals Corporation (0120G0)

Overview

Samyang Biopharmaceuticals Corporation is a specialized biopharmaceutical company that emerged from the pharmaceutical division of Samyang Corporation. Established as an independent entity in 2011, it strengthened its global competitiveness through a merger with Samyang Holdings in 2021. The company is dedicated to improving healthcare on a global scale by pioneering innovative research and development across diverse areas including medical devices, pharmaceuticals, and gene therapeutics.

Samyang Biopharmaceuticals is particularly notable for its leadership in polymer-based biodegradable sutures, leading the market as the first company in Korea and third globally to successfully commercialize synthetic absorbable surgical sutures made from high-molecular biodegradable materials. The company's extensive product portfolio encompasses a variety of medical devices, advanced cytotoxic anticancer drugs, and innovative drug delivery systems tailored for oncology and critical care applications.

Products and Services

• Biodegradable Sutures:

  Samyang Biopharmaceuticals has pioneered the development of polymer-based biodegradable sutures, offering surgeons an innovative solution that leads to enhanced patient recovery through effective wound management.

• Cytotoxic Anticancer Drugs:

  The company provides high-quality cytotoxic anticancer drugs, including paclitaxel, which are essential in chemotherapy treatment regimens. These drugs are developed to target cancer cells effectively with minimized side effects.

• Advanced Nanoparticle-based Injectable Therapies:

  Samyang Biopharmaceuticals specializes in cutting-edge nanoparticle drug delivery systems. These therapies are designed to improve the bioavailability and therapeutic effectiveness of medications, particularly in oncology.

• Incrementally Modified Drugs:

  Focused on oncology and critical care areas, the company's incrementally modified drugs provide enhanced therapeutic benefits through refined formulations, optimizing patient outcomes and treatment efficacy.

• Gene Therapeutics:

  Utilizing proprietary drug delivery platforms, Samyang has developed advanced gene therapies that leverage tissue-selective systems, facilitating targeted delivery of therapeutic genes to specific cells.

• Next-Generation Vaccines:

  The company is at the forefront of developing vaccines through novel gene delivery techniques, aiming to improve vaccine efficacy and safety through tailored delivery methods.